eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2010
vol. 35
 
Share:
Send email
Share:
abstract:

Review paper
Antiangiogenic treatment in renal cell carcinoma

Krzysztof Pastewka
,
Marek Zawadzki
,
Marcin Rudziński

(Centr Eur J Immunol 2010; 35 (4): 249-251)
Online publish date: 2011/01/13
View full text Get citation
 
Renal cell carcinoma (RCC) is the most lethal of all genitourinary tumors which standard and often curative treatment is based on radical nephrectomy or nephron sparing surgery. Since 2009 the treatment of metastatic and advanced RCC, following the cytoreductive surgery, has targeted antiangiogenic therapy combined with immunotherapy. The objective response rate to anti-angiogenic agents targeting VEGF, PDGF and thyrosine kinase inhibition like bevacizumab, sunitynib, sorafenib and others is almost twice higher than in previously used interferon and /or interleukin 2 immunotherapy. Future possibilities in stabilization of kidney cancer were discussed.
keywords:

renal cell carcinoma, angiogenesis, antiangiogenic therapy, immunotherapy
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.